Nagesh Kalakonda, MD, discusses final results from the L-MIND study, in which the combination of tafasitamab plus lenalidomide demonstrated durable responses and curative potential for patients with R/R DLBCL.
Nagesh Kalakonda, MD, discusses final results from the L-MIND study, in which the combination of tafasitamab plus lenalidomide demonstrated durable responses and curative potential for patients with R/R DLBCL.
Nagesh Kalakonda, MD, discusses...